KR880701099A - 경구 투여용 서방출형제제 - Google Patents

경구 투여용 서방출형제제

Info

Publication number
KR880701099A
KR880701099A KR1019870701020A KR870701020A KR880701099A KR 880701099 A KR880701099 A KR 880701099A KR 1019870701020 A KR1019870701020 A KR 1019870701020A KR 870701020 A KR870701020 A KR 870701020A KR 880701099 A KR880701099 A KR 880701099A
Authority
KR
South Korea
Prior art keywords
matrix
formulation according
xanthan gum
dosage form
formulation
Prior art date
Application number
KR1019870701020A
Other languages
English (en)
Inventor
마시모 클란치
레오나르도 겐티리니
루이찌 마펠리
마르코 마르코니
Original Assignee
마르티노 마그니
에우란드 이탈리아 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11160299&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880701099(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 마르티노 마그니, 에우란드 이탈리아 에스.피.에이. filed Critical 마르티노 마그니
Publication of KR880701099A publication Critical patent/KR880701099A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

경구 투여용 서방출형제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 천연 폴리사카라이드로 구성되며 지연효과를 부여하는 1종 이상의 메트릭스와 활성 성분으로 구성되는 것을 특징으로 하는 일정하고 서서히 방출하는 고형 투여 형태와 제제.
  2. 제1항에 있어서, 천연폴리사카라이드가 크산탄 검인 것이 특징인 제제.
  3. 크산탄 검과 1종 이상의 천연 또는 인공 중합체로 조성되는 메트릭스 메트릭스와 1종 이상의 활성 성분으로 구성되어 지연효과를 부여하며, 물 또는 위장액 중에서 서서히 및(또는) 신속히 수화 및 용해하며 그의 용해속도가 매체의 pH값의 기능에 의존하는 것이 특징인 일정하고 계속적으로 방출하는 고형투여 형태의 제제.
  4. 제3항에 있어서, 메트릭스 중량 백분률이 바람직하기로는 50내지 100%의 크산탄 검과 0 내지 50%의 1종 이상의 전술한 중합체인 것이 특징인 제제.
  5. 제3항에 있어서, 메트릭스가 크산탄 검 이외에 히드록시프로셀룰로오즈 또는 히드록시프로필메틸셀룰로오즈 또는 그들의 혼합물인 것이 특징인 제제.
  6. 제2,3,4 또는 5항에 있어서, 미리 숙정된 변성 옥수수전분(인스턴트 크리어 겔R)이 크산탄 검 대신에 사용한 것이 특징인 제제.
  7. 전술한 항중 1 또는 2 이상에 있어서, 정제, 캅셀제, 로젠지 등과 같은 서방출 의약 고형투여 형태로 제조된 것이 특징인 제제.
  8. 전술한 항중 1 또는 2 이상에서, 1종 이상의 활성 성분과 지연 메트릭스의 구성 이외에, 소망의 투여 형태를 얻기 위해 활제, 염료, 희석제, 감미료, 향료의 같은 불활성 부형제가 첨가된 제제.
  9. 전술한 항중 1 또는 2 이상의 항에서, 메트릭스가 1일 단일투여하기 위하여 약품 방출이 24시간까지 연장되도록 조성된 것이 특징인 제제.
  10. 전술한 목적을 위하여 실질적으로 전술한 바와 같이, 그리고 첨부된 실시예에서 예시한 바와 같이 경구투여에 적합한 서방출 약품을 제조하는 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870701020A 1986-03-07 1987-03-02 경구 투여용 서방출형제제 KR880701099A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT19675/86A IT1191674B (it) 1986-03-07 1986-03-07 Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
IT19675A/86 1986-03-07
PCT/EP1987/000124 WO1987005212A1 (en) 1986-03-07 1987-03-02 Formulation for preparing sustained release drugs for oral administration

Publications (1)

Publication Number Publication Date
KR880701099A true KR880701099A (ko) 1988-07-25

Family

ID=11160299

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870701020A KR880701099A (ko) 1986-03-07 1987-03-02 경구 투여용 서방출형제제

Country Status (12)

Country Link
US (1) US5047248A (ko)
EP (1) EP0261213B1 (ko)
JP (1) JP2617109B2 (ko)
KR (1) KR880701099A (ko)
CA (1) CA1316108C (ko)
DK (1) DK172117B1 (ko)
HK (1) HK12395A (ko)
IT (1) IT1191674B (ko)
NZ (1) NZ219523A (ko)
PT (1) PT84416B (ko)
WO (1) WO1987005212A1 (ko)
ZA (1) ZA871620B (ko)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
NL9201195A (nl) * 1992-07-03 1994-02-01 Tno Preparaat voor de gereguleerde afgifte van een werkzame stof en werkwijze ter bereiding van een dergelijk preparaat.
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5399354A (en) * 1993-05-28 1995-03-21 Mcneil-Ppc, Inc. Process for making a hard-candy based oral pharmaceutical lozenge containing an antacid
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
BE1009380A3 (nl) * 1995-03-14 1997-03-04 Universiteit Gent Lab Voor Far Stabiliserend samenstelling voor suspensie.
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
IN186245B (ko) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
DE69940557D1 (de) * 1998-12-11 2009-04-23 Nostrum Pharmaceuticals Inc Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CZ2002336A3 (cs) * 1999-07-30 2002-06-12 Smithkline Beecham Plc Multikomponentní farmaceutická dávková forma
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7276250B2 (en) * 2001-07-06 2007-10-02 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
CA2452872A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20040052851A1 (en) * 2002-09-16 2004-03-18 Graff Allan H. Modified release oral dosage form
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
AP1899A (en) 2003-08-08 2008-10-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
GB0320854D0 (en) 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US20050053648A1 (en) * 2003-09-08 2005-03-10 Chalmers Anne Marie Medication delivery device
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
AU2006269944A1 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
CN101304764B (zh) 2005-11-11 2012-12-05 旭化成化学株式会社 控释固体制剂
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
WO2014014645A1 (en) * 2012-07-17 2014-01-23 Miranda Technologies, Inc. Systems and methods for oral administration of a therapy
WO2017052455A1 (en) 2015-09-23 2017-03-30 Anara Ab Amylase fragments for blood glucose control
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
EP3251687A1 (en) 2016-06-01 2017-12-06 Centrum Innowacji Edoradca Sp. z o.o. Spolka Komandytowa Bioactive peptides for blood glucose control

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
DE2130545A1 (de) * 1971-06-19 1972-12-21 Merck Patent Gmbh Pharmazeutischer Formkoerper
US4332789A (en) * 1975-12-15 1982-06-01 Hoffmann-La Roche Inc. Pharmaceutical unit dosage forms
US4344857A (en) * 1975-12-22 1982-08-17 The United States Of America As Represented By The Secretary Of Agriculture Encapsulation by entrapment
US4163777A (en) * 1977-04-29 1979-08-07 Lewis/Howe Company Controlled antacid delivery form and method of treatment therewith
US4259341A (en) * 1977-06-01 1981-03-31 Merck & Co., Inc. Di- and tri-substituted thiazoles
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4375468A (en) * 1981-07-13 1983-03-01 Verex Laboratories, Inc. Constant order release aspirin composition and method of treating arthritis
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
DE3346571A1 (de) * 1983-12-23 1985-07-04 Bayer Ag, 5090 Leverkusen Oral retardierte acetylsalicylsaeureformulierungen
JPS60174728A (ja) * 1984-02-22 1985-09-09 Sato Seiyaku Kk 持効性製剤
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
DE3440288A1 (de) * 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung
BE901111A (fr) * 1984-11-22 1985-03-15 Benfar Representee Par Vanderl Composition pharmaceutiques a liberation prolongee, leur procede de preparation et leur utilisation.
SE8501094D0 (sv) * 1985-03-06 1985-03-06 Ulf Schroder Biologiskt aktiv komposition och forfarande for framstellning derav
GB8507779D0 (en) * 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents

Also Published As

Publication number Publication date
JP2617109B2 (ja) 1997-06-04
CA1316108C (en) 1993-04-13
DK582287A (da) 1987-11-05
IT1191674B (it) 1988-03-23
DK582287D0 (da) 1987-11-05
IT8619675A0 (it) 1986-03-07
PT84416A (en) 1987-04-01
EP0261213B1 (en) 1992-08-05
NZ219523A (en) 1990-08-28
AU603098B2 (en) 1990-11-08
IT8619675A1 (it) 1987-09-07
EP0261213A1 (en) 1988-03-30
AU7288387A (en) 1987-09-28
DK172117B1 (da) 1997-11-17
PT84416B (pt) 1989-10-04
WO1987005212A1 (en) 1987-09-11
US5047248A (en) 1991-09-10
HK12395A (en) 1995-02-03
ZA871620B (en) 1988-02-24
JPS63503225A (ja) 1988-11-24

Similar Documents

Publication Publication Date Title
KR880701099A (ko) 경구 투여용 서방출형제제
Alam et al. FDA‐Approved Natural Polymers for Fast Dissolving Tablets
CA2072933A1 (en) Mechanically-stable, readily-disintegratable tablets made of small preformed particles containing active ingredients
KR950700115A (ko) 1차 알콜 관능기를 함유하는 다당질 벽 미소캡슐 및 그를 함유하는 조성물(polysaccharide wall microcapsules containing primary alcohol functions and compositions containing same)
KR880007051A (ko) 틀니 안정용 조성물
NO175240C (no) Fremgangsmåte for fremstilling av et langsomt frigivende farmasöytisk preparat som omfatter sekundære granuler
FR2618673A1 (fr) Formule medicamenteuse a liberation controlee
NO973730L (no) Faste virkestofftilberedninger
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
RU92004423A (ru) Препарат из растений curcuma
KR960703570A (ko) 부형제와 함께 프로게스테론 및 폴리에틸렌글리콜을 함유하는 경구투여용 신규약제(a novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together wtth an excipient)
JPS57197214A (en) Rapid-releasing microcapsule and its preparation
KR880004803A (ko) 분무 건조된 아세트아미노펜
US4143129A (en) Cephalexin tablets
JP5416716B2 (ja) グリコーゲンおよびアルギン酸塩の会合体に基づく徐放性製剤
RU2297221C2 (ru) Фармацевтическая композиция, включающая ингибитор липазы и глюкоманнан
JPH10291928A (ja) ソフトカプセル
KR910004479B1 (ko) 슈우크럴페이트를 유효성분으로 함유하는 현탁액
KR870002845A (ko) 식욕조절 및 위암억제용 조성물
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
Ratnaparkhi et al. Natural polymers in fast dissolving tablets
KR930021195A (ko) 경구투여용 서방출형제제
KR880004801A (ko) 서방성 약학적 조성물
Nautyal et al. FDA-Approved Natural Disintrgrant for Fast Dissolving Tablets
KR930021206A (ko) 시타라빈 옥포스페이트 경질 캡슐제

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid